SCF E3 ubiquitin ligases as anticancer targets

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 347-356

  Jia, L ^a,b   Sun, Y ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Anticancer target; Cullins; Drug discovery; F box proteins; Neddylation; RING ligases; SCF E3 ubiquitin ligase; Ubiquitin proteasome system

Indexed keywords

BETA TRCP1; BETA TRCP2; BORTEZOMIB; CULLIN; DNA; F BOX PROTEIN; LIGASE INHIBITOR; MLN4924; NEDD8 PROTEIN; RING FINGER PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SCF UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; DNA DAMAGE; DNA REPLICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INACTIVATION; FATIGUE; GENETIC TRANSCRIPTION; HUMAN; HYPERTRANSAMINASEMIA; LUNG CANCER; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; SKP CULLIN F-BOX PROTEIN LIGASES;

EID: 79951689476     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519734     Document Type: Article

References (136)

1. Hershko, A.; Ciechanover, A.; Varshavsky, A. Basic Medical Research Award. The ubiquitin system. Nat. Med. 2000, 6, 1073-1081.
2. Pickart, C. M. Back to the future with ubiquitin. Cell 2004, 116, 181-190.
3. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998, 17, 7151-7160.
4. Chen, Z. J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 2005, 7, 758-765.
5. Pickart, C. M. Ubiquitin in chains. Trends Biochem. Sci. 2000, 25, 544-548.
6. Spence, J.; Sadis, S.; Haas, A. L.; Finley, D. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell Biol. 1995, 15, 1265-1273.
7. Deshaies, R. J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 1999, 15, 435-467.
8. Sun, Y.; Tan, M.; Duan, H.; Swaroop, M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid. Redox Signal. 2001, 3, 635-650.
9. Soucy, T. A.; Smith, P. G.; Milhollen, M. A.; Berger, A. J.; Gavin, J. M.; Adhikari, S.; Brownell, J. E.; Burke, K. E.; Cardin, D. P.; Critchley, S.; Cullis, C. A.; Doucette, A.; Garnsey, J. J.; Gaulin, J. L.; Gershman, R. E.; Lublinsky, A. R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E. J.; Peluso, S.; Rezaei, M.; Sintchak, M. D.; Talreja, T.; Thomas, M. P.; Traore, T.; Vyskocil, S.; Weatherhead, G. S.; Yu, J.; Zhang, J.; Dick, L. R.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Langston, S. P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458, 732-736.
10. Nakayama, K. I.; Nakayama, K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 2005, 16, 323-333.
11. Nakayama, K. I.; Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6, 369-381.
12. Deshaies, R. J.; Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78, 399-434.
13. Jia, L.; Sun, Y. RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival. Cell Div. 2009, 4, 16.
14. Petroski, M. D.; Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6, 9-20.
15. Skaar, J. R.; D'Angiolella, V.; Pagan, J. K.; Pagano, M. SnapShot: F box proteins II. Cell 2009, 137, 1358, 1358 e1351.
16. Zheng, N.; Schulman, B. A.; Song, L.; Miller, J. J.; Jeffrey, P. D.; Wang, P.; Chu, C.; Koepp, D. M.; Elledge, S. J.; Pagano, M.; Conaway, R. C.; Conaway, J. W.; Harper, J. W.; Pavletich, N. P. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416, 703-709.
17. Wu, K.; Fuchs, S. Y.; Chen, A.; Tan, P.; Gomez, C.; Ronai, Z.; Pan, Z. Q. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol. Cell Biol. 2000, 20, 1382-1393.
18. Duda, D. M.; Borg, L. A.; Scott, D. C.; Hunt, H. W.; Hammel, M.; Schulman, B. A. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008, 134, 995-1006.
19. Goldenberg, S. J.; Cascio, T. C.; Shumway, S. D.; Garbutt, K. C.; Liu, J.; Xiong, Y.; Zheng, N. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004, 119, 517-528.
20. Kamura, T.; Conrad, M. N.; Yan, Q.; Conaway, R. C.; Conaway, J. W. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev. 1999, 13, 2928-2933.
21. Yamoah, K.; Oashi, T.; Sarikas, A.; Gazdoiu, S.; Osman, R.; Pan, Z. Q. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 12230-12235.
22. Duan, H.; Wang, Y.; Aviram, M.; Swaroop, M.; Loo, J. A.; Bian, J.; Tian, Y.; Mueller, T.; Bisgaier, C. L.; Sun, Y. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol. Cell Biol. 1999, 19, 3145-3155.
23. Kamura, T.; Koepp, D. M.; Conrad, M. N.; Skowyra, D.; Moreland, R. J.; Iliopoulos, O.; Lane, W. S.; Kaelin, W. G.; Elledge, S. J.; Conaway, R. C.; Harper, J. W.; Conaway, J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284, 657-661.
24. Ohta, T.; Michel, J. J.; Schottelius, A. J.; Xiong, Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell. 1999, 3, 535-541.
25. Tan, P.; Fuchs, S. Y.; Chen, A.; Wu, K.; Gomez, C.; Ronai, Z.; Pan, Z.-Q. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IkBa. Mol Cell. 1999, 3, 527-533.
26. Jin, J.; Cardozo, T.; Lovering, R. C.; Elledge, S. J.; Pagano, M.; Harper, J. W. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004, 18, 2573-2580.
27. Jackson, S.; Xiong, Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem. Sci. 2009, 34, 562-570.
28. Frescas, D.; Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer. 2008, 8, 438-449.
29. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5, 596-613.
30. Welcker, M.; Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer. 2008, 8, 83-93.
31. Swaroop, M.; Wang, Y.; Miller, P.; Duan, H.; Jatkoe, T.; Madore, S.; Sun, Y. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: Chip profiling implicates its role in cell cycle regulation. Oncogene 2000, 19, 2855-2866.
32. Furukawa, M.; Ohta, T.; Xiong, Y. Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins. J. Biol. Chem. 2002, 277, 15758-15765.
33. Seol, J. H.; Feldman, R. M. R.; Zachariae, W. Z.; Shevchenko, A.; Correll, C. C.; Lyapina, S.; Chi, Y.; Galova, M.; Claypool, J.; Sandmeyer, S.; Nasmyth, K.; Shevchenko, A.; Deshaies, R. J. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev. 1999, 13, 1614-1626.
34. Gu, Q.; Tan, M.; Sun, Y. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. Cancer Res. 2007, 67, 3616-3625.
35. Kamura, T.; Maenaka, K.; Kotoshiba, S.; Matsumoto, M.; Kohda, D.; Conaway, R. C.; Conaway, J. W.; Nakayama, K. I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004, 18, 3055-3065.
36. Tan, M.; Davis, S. W.; Saunders, T. L.; Zhu, Y.; Sun, Y. RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 6203-6208.
37. Jia, L.; Soengas, M. S.; Sun, Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009, 69, 4974-4982.
38. Li, X.; Zhao, Q.; Liao, R.; Sun, P.; Wu, X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J. Biol. Chem. 2003, 278, 30854-30858.
39. Mendez, J.; Zou-Yang, X. H.; Kim, S. Y.; Hidaka, M.; Tansey, W. P.; Stillman, B. Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol. Cell. 2002, 9, 481-491.
40. Hu, J.; Xiong, Y. An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage. J. Biol. Chem. 2006, 281, 3753-3756.
41. Nishitani, H.; Sugimoto, N.; Roukos, V.; Nakanishi, Y.; Saijo, M.; Obuse, C.; Tsurimoto, T.; Nakayama, K. I.; Nakayama, K.; Fujita, M.; Lygerou, Z.; Nishimoto, T. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 2006, 25, 1126-1136.
42. Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L. V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V. C.; Takaoka, M.; Nakagawa, H.; Tort, F.; Fugger, K.; Johansson, F.; Sehested, M.; Andersen, C. L.; Dyrskjot, L.; Orntoft, T.; Lukas, J.; Kittas, C.; Helleday, T.; Halazonetis, T. D.; Bartek, J.; Gorgoulis, V. G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444, 633-637.
43. Di Micco, R.; Fumagalli, M.; Cicalese, A.; Piccinin, S.; Gasparini, P.; Luise, C.; Schurra, C.; Garre, M.; Nuciforo, P. G.; Bensimon, A.; Maestro, R.; Pelicci, P. G.; d'Adda di Fagagna, F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444, 638-642.
44. Hook, S. S.; Lin, J. J.; Dutta, A. Mechanisms to control rereplication and implications for cancer. Curr. Opin. Cell Biol. 2007, 19, 663-671.
45. Sun, Y. Alteration of SAG mRNA in human cancer cell lines: Requirement for the RING finger domain for apoptosis protection. Carcinogenesis 1999, 20, 1899-1903.
46. Yang, E. S.; Park, J. W. Regulation of nitric oxide-induced apoptosis by sensitive to apoptosis gene protein. Free Radic. Res. 2006, 40, 279-284.
47. Chanalaris, A.; Sun, Y.; Latchman, D. S.; Stephanou, A. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J. Mol. Cell Cardiol. 2003, 35, 257-264.
48. Kim, S. Y.; Kim, M. Y.; Mo, J. S.; Park, J. W.; Park, H. S. SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the down-regulation of ROS generation and JNK signaling. Neurosci. Lett. 2007, 413, 132-136.
49. Lee, S. J.; Yang, E. S.; Kim, S. Y.; Shin, S. W.; Park, J. W. Regulation of heat shock-induced apoptosis by sensitive to apoptosis gene protein. Free Radic. Biol. Med. 2008, 45, 167-176.
50. He, H.; Gu, Q.; Zheng, M.; Normolle, D.; Sun, Y. SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 2008, 29, 858-865.
51. Duan, H.; Tsvetkov, L. M.; Liu, Y.; Song, Y.; Swaroop, M.; Wen, R.; Kung, H. F.; Zhang, H.; Sun, Y. Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation. Mol. Carcinog. 2001, 30, 37-46.
52. Tan, M.; Gallegos, J. R.; Gu, Q.; Huang, Y.; Li, J.; Jin, Y.; Lu, H.; Sun, Y. SAG/ROC-SCFbeta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 2006, 8, 1042-1054.
53. Tan, M.; Gu, Q.; He, H.; Pamarthy, D.; Semenza, G. L.; Sun, Y. SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1alpha ubiquitination and degradation. Oncogene 2008, 27, 1404-1411.
54. Gu, Q.; Bowden, T.G.; Normolle, D.; Sun, Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage dependent targeting of c-Jun/AP1 and IkB/NF-kB. J. Cell. Biol. 2007, 178, 1009-1023.
55. Jia, L.; Yang, J.; Hao, X.; Zheng, M.; He, H.; Xiong, X.; Xu, L.; Sun, Y. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin. Cancer Res. 2010, 16, 814-824.
56. Huang, Y.; Duan, H.; Sun, Y. Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol. Carcinog. 2001, 30, 62-70.
57. Sasaki, H.; Yukiue, H.; Kobayashi, Y.; Moriyama, S.; Nakashima, Y.; Kaji, M.; Fukai, I.; Kiriyama, M.; Yamakawa, Y.; Fujii, Y. Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer. Int. J. Cancer. 2001, 95, 375-377.
58. Nalepa, G.; Wade Harper, J. Therapeutic anti-cancer targets up-stream of the proteasome. Cancer Treat Rev. 2003, 29 Suppl 1, 49-57.
59. Masuda, T. A.; Inoue, H.; Sonoda, H.; Mine, S.; Yoshikawa, Y.; Nakayama, K.; Mori, M. Clinical and biological significance of Sphase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002, 62, 3819-3825.
60. Masuda, T. A.; Inoue, H.; Nishida, K.; Sonoda, H.; Yoshikawa, Y.; Kakeji, Y.; Utsunomiya, T.; Mori, M. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin. Cancer Res. 2003, 9, 5693-5698.
61. Hershko, D. D.; Shapira, M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006, 107, 668-675.
62. Shapira, M.; Ben-Izhak, O.; Linn, S.; Futerman, B.; Minkov, I.; Hershko, D. D. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005, 103, 1336-1346.
63. Signoretti, S.; Di Marcotullio, L.; Richardson, A.; Ramaswamy, S.; Isaac, B.; Rue, M.; Monti, F.; Loda, M.; Pagano, M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 2002, 110, 633-641.
64. Forozan, F.; Mahlamaki, E. H.; Monni, O.; Chen, Y.; Veldman, R.; Jiang, Y.; Gooden, G. C.; Ethier, S. P.; Kallioniemi, A.; Kallioniemi, O. P. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 2000, 60, 4519-4525.
65. Sonoda, H.; Inoue, H.; Ogawa, K.; Utsunomiya, T.; Masuda, T. A.; Mori, M. Significance of skp2 expression in primary breast cancer. Clin. Cancer Res. 2006, 12, 1215-1220.
66. Shim, E. H.; Johnson, L.; Noh, H. L.; Kim, Y. J.; Sun, H.; Zeiss, C.; Zhang, H. Expression of the F-Box Protein SKP2 Induces Hyperplasia, Dysplasia, and Low-Grade Carcinoma in the Mouse Prostate. Cancer Res. 2003, 63, 1583-1588.
67. Latres, E.; Chiarle, R.; Schulman, B. A.; Pavletich, N. P.; Pellicer, A.; Inghirami, G.; Pagano, M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 2515-2520.
68. Timmerbeul, I.; Garrett-Engele, C. M.; Kossatz, U.; Chen, X.; Firpo, E.; Grunwald, V.; Kamino, K.; Wilkens, L.; Lehmann, U.; Buer, J.; Geffers, R.; Kubicka, S.; Manns, M. P.; Porter, P. L.; Roberts, J. M.; Malek, N. P. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 14009-14014.
69. Lin, H. K.; Chen, Z.; Wang, G.; Nardella, C.; Lee, S. W.; Chan, C. H.; Yang, W. L.; Wang, J.; Egia, A.; Nakayama, K. I.; Cordon-Cardo, C.; Teruya-Feldstein, J.; Pandolfi, P. P. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464, 374-379.
70. Katagiri, Y.; Hozumi, Y.; Kondo, S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol. Sci. 2006, 42(3), 215-224.
71. Kudo, Y.; Kitajima, S.; Ogawa, I.; Kitagawa, M.; Miyauchi, M.; Takata, T. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther. 2005, 4, 471-476.
72. Lee, S. H.; McCormick, F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J. Mol. Med. 2005, 83, 296-307.
73. Sumimoto, H.; Yamagata, S.; Shimizu, A.; Miyoshi, H.; Mizuguchi, H.; Hayakawa, T.; Miyagishi, M.; Taira, K.; Kawakami, Y. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 2005, 12, 95-100.
74. Jiang, F.; Caraway, N. P.; Li, R.; Katz, R. L. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 2005, 24, 3409-3418.
75. Yokoi, S.; Yasui, K.; Saito-Ohara, F.; Koshikawa, K.; Iizasa, T.; Fujisawa, T.; Terasaki, T.; Horii, A.; Takahashi, T.; Hirohashi, S.; Inazawa, J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am. J. Pathol. 2002, 161, 207-216.
76. Winston, J. T.; Strack, P.; Beer-Romero, P.; Chu, C. Y.; Elledge, S. J.; Harper, J. W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiq-uitination in vitro. Genes Dev. 1999, 13, 270-283.
77. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18, 621-663.
78. Dorrello, N. V.; Peschiaroli, A.; Guardavaccaro, D.; Colburn, N. H.; Sherman, N. E.; Pagano, M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314, 467-471.
79. Dehan, E.; Bassermann, F.; Guardavaccaro, D.; Vasiliver-Shamis, G.; Cohen, M.; Lowes, K. N.; Dustin, M.; Huang, D. C.; Taunton, J.; Pagano, M. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell. 2009, 33, 109-116.
80. Kudo, Y.; Guardavaccaro, D.; Santamaria, P. G.; Koyama-Nasu, R.; Latres, E.; Bronson, R.; Yamasaki, L.; Pagano, M. Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol. Cell Biol. 2004, 24, 8184-8194.
81. Belaidouni, N.; Peuchmaur, M.; Perret, C.; Florentin, A.; Benarous, R.; Besnard-Guerin, C. Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene 2005, 24, 2271-2276.
82. Tang, W.; Li, Y.; Yu, D.; Thomas-Tikhonenko, A.; Spiegelman, V. S.; Fuchs, S. Y. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res. 2005, 65, 1904-1908.
83. Muerkoster, S.; Arlt, A.; Sipos, B.; Witt, M.; Grossmann, M.; Kloppel, G.; Kalthoff, H.; Folsch, U. R.; Schafer, H. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 2005, 65, 1316-1324.
84. Marin, I. Diversification of the cullin family. BMC Evol. Biol. 2009, 9, 267.
85. Salon, C.; Brambilla, E.; Brambilla, C.; Lantuejoul, S.; Gazzeri, S.; Eymin, B. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J. Pathol. 2007, 213, 303-310.
86. Park, S. W.; Chung, N. G.; Hur, S. Y.; Kim, H. S.; Yoo, N. J.; Lee, S. H. Mutational analysis of hypoxia-related genes HIF1alpha and CUL2 in common human cancers. APMIS 2009, 117, 880-885.
87. Laszlo, G. S.; Cooper, J. A. Restriction of Src activity by Cullin-5. Curr. Biol. 2009, 19, 157-162.
88. Johnson, A. E.; Le, I. P.; Buchwalter, A.; Burnatowska-Hledin, M. A. Estrogen-dependent growth and estrogen receptor (ER)-alpha concentration in T47D breast cancer cells are inhibited by VACM-1, a cul 5 gene. Mol. Cell Biochem. 2007, 301, 13-20.
89. Chen, L. C.; Manjeshwar, S.; Lu, Y.; Moore, D.; Ljung, B. M.; Kuo, W. L.; Dairkee, S. H.; Wernick, M.; Collins, C.; Smith, H. S. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 1998, 58, 3677-3683.
90. Melchor, L.; Saucedo-Cuevas, L. P.; Munoz-Repeto, I.; Rodriguez-Pinilla, S. M.; Honrado, E.; Campoverde, A.; Palacios, J.; Nathanson, K. L.; Garcia, M. J.; Benitez, J. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res. 2009, 11, R86.
91. Schindl, M.; Gnant, M.; Schoppmann, S. F.; Horvat, R.; Birner, P. Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res. 2007, 27, 949-952.
92. Yasui, K.; Arii, S.; Zhao, C.; Imoto, I.; Ueda, M.; Nagai, H.; Emi, M.; Inazawa, J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002, 35, 1476-1484.
93. Hung, M. S.; Mao, J. H.; Xu, Z.; Yang, C. T.; Yu, J. S.; Harvard, C.; Lin, Y. C.; Bravo, D. T.; Jablons, D. M.; You, L. Cul4A is an oncogene in malignant pleural mesothelioma. J. Cell Mol. Med. 2009.
94. Liu, L.; Lee, S.; Zhang, J.; Peters, S. B.; Hannah, J.; Zhang, Y.; Yin, Y.; Koff, A.; Ma, L.; Zhou, P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol. Cell. 2009, 34, 451-460.
95. Kane, R. C.; Bross, P. F.; Farrell, A. T.; Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8, 508-513.
96. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657.
97. Colson, K.; Doss, D. S.; Swift, R.; Tariman, J.; Thomas, T. E. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin. J. Oncol. Nurs. 2004, 8, 473-480.
98. Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Therapy 2003, 2, 623-629.
99. Sun, Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8, 645-654.
100. Hao, B.; Zheng, N.; Schulman, B. A.; Wu, G.; Miller, J. J.; Pagano, M.; Pavletich, N. P. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell. 2005, 20, 9-19.
101. Huang, J.; Sheung, J.; Dong, G.; Coquilla, C.; Daniel-Issakani, S.; Payan, D. G. High-throughput screening for inhibitors of the E3 ubiquitin ligase APC. Methods Enzymol. 2005, 399, 740-754.
102. Xu, S.; Patel, P.; Abbasian, M.; Giegel, D.; Xie, W.; Mercurio, F.; Cox, S. In vitro SCFbeta-Trcp1-mediated IkappaBalpha ubiquitination assay for high-throughput screen. Methods Enzymol. 2005, 399, 729-740.
103. Sakamoto, K. M.; Kim, K. B.; Kumagai, A.; Mercurio, F.; Crews, C. M.; Deshaies, R. J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 8554-8559.
104. Sun, Y. Overview of approaches for screening for ubiquitin ligase inhibitors. Methods Enzymol. 2005, 399, 654-663.
105. Chen, Q.; Xie, W.; Kuhn, D. J.; Voorhees, P. M.; Lopez-Girona, A.; Mendy, D.; Corral, L. G.; Krenitsky, V. P.; Xu, W.; Moutouh de Parseval, L.; Webb, D. R.; Mercurio, F.; Nakayama, K. I.; Nakayama, K.; Orlowski, R. Z. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008, 111, 4690-4699.
106. Xirodimas, D. P. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem. Soc. Trans. 2008, 36, 802-806.
107. Merlet, J.; Burger, J.; Gomes, J. E.; Pintard, L. Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization. Cell Mol. Life Sci. 2009, 66, 1924-1938.
108. Pan, Z. Q.; Kentsis, A.; Dias, D. C.; Yamoah, K.; Wu, K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004, 23, 1985-1997.
109. Soucy, T. A.; Smith, P. G.; Rolfe, M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 2009, 15, 3912-3916.
110. Brownell, J. E.; Sintchak, M. D.; Gavin, J. M.; Liao, H.; Bruzzese, F. J.; Bump, N. J.; Soucy, T. A.; Milhollen, M. A.; Yang, X.; Burkhardt, A. L.; Ma, J.; Loke, H. K.; Lingaraj, T.; Wu, D.; Hamman, K. B.; Spelman, J. J.; Cullis, C. A.; Langston, S. P.; Vyskocil, S.; Sells, T. B.; Mallender, W. D.; Visiers, I.; Li, P.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Dick, L. R. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell. 2010, 37, 102-111.
111. Swords, R. T.; Kelly, K. R.; Smith, P. G.; Garnsey, J. J.; Mahalingam, D.; Medina, E.; Oberheu, K.; Padmanabhan, S.; O'Dwyer, M.; Nawrocki, S. T.; Giles, F. J.; Carew, J. S. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115, 3796-3800.
112. Milhollen, M. A.; Traore, T.; Adams-Duffy, J.; Thomas, M. P.; Berger, A. J.; Dang, L.; Dick, L. R.; Garnsey, J. J.; Koenig, E.; Langston, S. P.; Manfredi, M.; Narayanan, U.; Rolfe, M.; Staudt, L. M.; Soucy, T. A.; Yu, J.; Zhang, J.; Bolen, J. B.; Smith, P. G. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-B-dependent lymphoma. Blood 2010, 116, 1515-1523.
113. Yen, H. C.; Elledge, S. J. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 2008, 322, 923-929.
114. Yen, H. C.; Xu, Q.; Chou, D. M.; Zhao, Z.; Elledge, S. J. Global protein stability profiling in mammalian cells. Science 2008, 322, 918-923.
115. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
116. Kamizono, S.; Hanada, T.; Yasukawa, H.; Minoguchi, S.; Kato, R.; Minoguchi, M.; Hattori, K.; Hatakeyama, S.; Yada, M.; Morita, S.; Kitamura, T.; Kato, H.; Nakayama, K.; Yoshimura, A. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 2001, 276, 12530-12538.
117. Furukawa, M.; He, Y. J.; Borchers, C.; Xiong, Y. Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat. Cell Biol. 2003, 5, 1001-1007.
118. Furukawa, M.; Xiong, Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell Biol. 2005, 25, 162-171.
119. Pintard, L.; Willis, J. H.; Willems, A.; Johnson, J. L.; Srayko, M.; Kurz, T.; Glaser, S.; Mains, P. E.; Tyers, M.; Bowerman, B.; Peter, M. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 2003, 425, 311-316.
120. Angers, S.; Thorpe, C. J.; Biechele, T. L.; Goldenberg, S. J.; Zheng, N.; MacCoss, M. J.; Moon, R. T. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat. Cell Biol. 2006, 8, 348-357.
121. Niture, S. K.; Jaiswal, A. K. Prothymosin-alpha mediates nuclear import of the INrf2/Cul3 Rbx1 complex to degrade nuclear Nrf2. J. Biol. Chem. 2009, 284, 13856-13868.
122. Jin, Z.; Li, Y.; Pitti, R.; Lawrence, D.; Pham, V. C.; Lill, J. R.; Ashkenazi, A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137, 721-735.
123. Wilkins, A.; Ping, Q.; Carpenter, C. L. RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex. Genes Dev. 2004, 18, 856-861.
124. Zhang, H. F.; Tomida, A.; Koshimizu, R.; Ogiso, Y.; Lei, S.; Tsuruo, T. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res. 2004, 64, 1114-1121.
125. Lee, Y. R.; Yuan, W. C.; Ho, H. C.; Chen, C. H.; Shih, H. M.; Chen, R. H. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 2010, 2010 Apr 13.
126. Nag, A.; Bagchi, S.; Raychaudhuri, P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 2004, 64, 8152-8155.
127. Banks, D.; Wu, M.; Higa, L. A.; Gavrilova, N.; Quan, J.; Ye, T.; Kobayashi, R.; Sun, H.; Zhang, H. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle. 2006, 5, 1719-1729.
128. Hu, J.; McCall, C. M.; Ohta, T.; Xiong, Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat. Cell Biol. 2004, 6, 1003-1009.
129. Hu, J.; Zacharek, S.; He, Y. J.; Lee, H.; Shumway, S.; Duronio, R. J.; Xiong, Y. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev. 2008, 22, 866-871.
130. Huang, J.; Chen, J. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene 2008, 27, 4056-4064.
131. Wertz, I. E.; O'Rourke, K. M.; Zhang, Z.; Dornan, D.; Arnott, D.; Deshaies, R. J.; Dixit, V. M. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004, 303, 1371-1374.
132. Jin, J.; Arias, E. E.; Chen, J.; Harper, J. W.; Walter, J. C. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell. 2006, 23, 709-721.
133. Higa, L. A.; Mihaylov, I. S.; Banks, D. P.; Zheng, J.; Zhang, H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat. Cell Biol. 2003, 5, 1008-1015.
134. Zhong, W.; Feng, H.; Santiago, F. E.; Kipreos, E. T. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature 2003, 423, 885-889.
135. Feng, L.; Allen, N. S.; Simo, S.; Cooper, J. A. Cullin 5 regulates Dab1 protein levels and neuron positioning during cortical development. Genes Dev. 2007, 21, 2717-2730.
136. Xu, X.; Sarikas, A.; Dias-Santagata, D. C.; Dolios, G.; Lafontant, P. J.; Tsai, S. C.; Zhu, W.; Nakajima, H.; Nakajima, H. O.; Field, L. J.; Wang, R.; Pan, Z. Q. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol. Cell. 2008, 30, 403-414.